IAS 2009 : More Than Half of People With HIV Might Have Cognitive Impairment - by David Evans

A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube
Back to home » Top Stories » IAS 2009
IAC 2008 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
Cape Town, South Africa
July 19-22, 2009

emailprint

More Than Half of People With HIV Might Have Cognitive Impairment

July 23, 2009

By David Evans

Researchers with the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) report that 53 percent of their cohort of HIV-positive patients has at least mild impairment in thinking, memory and physical coordination—known as cognitive impairment. These data were presented at the Fifth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town.

Previously reported research indicates that HIV, by itself, can lead to cognitive impairment. People with HIV often have other cofactors—also known as comorbidities—that can lead to cognitive impairment; examples include age, diabetes and hepatitis coinfection. Because of this, researchers are turning their attention to quantifying how these various comorbidities might together increase the risk of cognitive decline.

In a follow-up to data originally presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI) in Montreal, Igor Grant, MD, from the University of California at San Diego reported on 1,555 HIV-positive patients enrolled at six university sites across the United States. The average age of the study participants was 43, 77 percent were male, 61 percent were non-white, and 28 percent had a history of injection drug use. Researchers compared the level of cognitive impairment with comorbidities.

Overall, 53 percent were found to have at least some cognitive impairment. Grant’s group found that those with comorbidities were more likely to have greater cognitive impairment. Of those with minimal impairment, 39 percent had comorbidities; 54 percent with moderate impairment had comorbidities; and 73 percent with severe impairment had comorbidities. Grant’s team also found that a greater number of comorbidities was linked with an increasingly severe degree of cognitive impairment.

The authors conclude that HIV and additional comorbidities do combine to increase the risk and severity of cognitive impairment.

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)

More from IAS 2009

Starting and Switching Treatment

July 31, 2009
South African Study: Nurses Comparable to Doctors in Monitoring HIV Management
July 30, 2009
Acyclovir Slows HIV Disease Progression, But Fails to Reduce HIV Transmission
July 27, 2009
Switch From Norvir-Boosted to Unboosted Reyataz Safe and Effective
July 24, 2009
Kaletra Is Better Than Viramune for Kids Exposed to Viramune at Birth
Study Hints That Micronutrient Supplement Might Help HIV-Positive Kids
A Quad NRTI Regimen Fails to Perform
July 23, 2009
HIV Treatment Effective Without Laboratory Monitoring in Southern Africa Study
Viramune Has Similar Efficacy to Reyataz
July 22, 2009
Pediatric Viramune May Still Work as Treatment in Kids Exposed at Birth
Triple-Drug Regimen Works Well for Heavily Treatment-Experienced Patients
Efavirenz Five-Days-On, Two-Off, Works as Well as Continuous Treatment
People on Sustiva Have Less Risk for Treatment Failure Than People on Kaletra
Substantial Single-Year Gains in ARV Access in 2008
July 21, 2009
Isentress Going Strong After Three Years in Treatment Starters
More Than Half Could Need Treatment Within 2 Years of Infection
July 20, 2009
Pediatric HIV: Successes and Challenges
GRACE Shows Similar Treatment Response Rates in Women and Men on Prezista Treatment
CD4 Counts Key to AIDS-Free Survival While on HIV Treatment

Women and HIV

July 28, 2009
Menopause May Occur Earlier in HIV-Positive Women
July 24, 2009
No Transmission and Few Birth Defects in Babies Born to African Mothers on HIV Treatment
July 22, 2009
Mma Bana: Lowest-Ever Mother-to-Child HIV Transmission Rates With Combo Therapy in Botswana
July 20, 2009
GRACE Shows Similar Treatment Response Rates in Women and Men on Prezista Treatment

HIV/AIDS Complications

August 3, 2009
New Studies Question Abacavir Role in Heart Attack Risk
July 30, 2009
Perhaps More Lipodystrophy With Sustiva?
July 29, 2009
High Prevalence of Vitamin D Deficiency in HIV-Positive Men
July 28, 2009
Menopause May Occur Earlier in HIV-Positive Women
July 27, 2009
Chronic Stress and Non-AIDS Diseases—Is There a Link?
July 23, 2009
Zinc Supplements Prevent Immune Decline in Chronic Substance Users
Efavirenz, Race Linked to Vitamin D Deficiency
Cancer Rates Are Lower, but Still Present at Higher CD4 Levels
More Than Half of People With HIV Might Have Cognitive Impairment
July 22, 2009
ARV Therapy of Little Benefit in Preventing Anal Cancer
ARV Treatment Eases Cape Town TB Rates
July 21, 2009
ARV Treatment Protects Against Malaria in Ugandan Study

Experimental HIV Drugs

July 28, 2009
Once- vs. Twice-Daily Kaletra for Treatment Veterans
July 27, 2009
Two Studies Explore Switch to Boosted Prezista Monotherapy
July 22, 2009
Efavirenz Five-Days-On, Two-Off, Works as Well as Continuous Treatment
July 21, 2009
Selzentry Comparable to Sustiva After 96 Weeks in Treatment Naives
Shionogi-GSK Integrase Inhibitor Shows Promise

HIV Transmission and Prevention

July 30, 2009
Acyclovir Slows HIV Disease Progression, But Fails to Reduce HIV Transmission
July 24, 2009
No Transmission and Few Birth Defects in Babies Born to African Mothers on HIV Treatment
July 22, 2009
Mma Bana: Lowest-Ever Mother-to-Child HIV Transmission Rates With Combo Therapy in Botswana
July 21, 2009
Circumcision Protects Insertive MSM Partners

Global HIV/AIDS

July 21, 2009
ARV Treatment Protects Against Malaria in Ugandan Study


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.